Nexsen Ltd
NXN
Company Profile
Business description
Nexsen Ltd is a nanobiotechnology company for the development of biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural and biosecurity applications. Its products include: GBS Rapid Sensor, Chronic Kidney Disease (CKD), Bovine Mastitis, Acute Kidney Injury (AKI), and Biosecurity Pathogen Tests (x2).
Contact
4 Bridge Street
Suite 1005
SydneyNSW2000
AUST: +61 291745388
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
ASX listed bank overvalued despite strong earnings
Profit beats drive shares higher for Australia’s largest asset manager.
stocks
After earnings, is Amazon a buy, a sell, or fairly valued?
After the launch of Amazon Supply Chain Services, here’s what we think of the stock.
stocks
ASX retail share expected to recover despite choppy conditions
Weakening consumer demand a temporary headwind for ASX retailer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,897.80 | 30.10 | -0.34% |
| CAC 40 | 8,112.57 | 89.51 | -1.09% |
| DAX 40 | 24,338.63 | 324.98 | -1.32% |
| Dow JONES (US) | 49,609.16 | 12.19 | 0.02% |
| FTSE 100 | 10,233.07 | 43.88 | -0.43% |
| HKSE | 26,393.71 | 232.57 | -0.87% |
| NASDAQ | 26,247.08 | 440.88 | 1.71% |
| Nikkei 225 | 63,216.12 | 502.47 | 0.80% |
| NZX 50 Index | 13,111.52 | 63.61 | -0.48% |
| S&P 500 | 7,398.93 | 61.82 | 0.84% |
| S&P/ASX 200 | 8,657.20 | 33.10 | -0.38% |
| SSE Composite Index | 4,179.95 | 0.14 | -0.00% |